Back to Man Group plc Man Group plc

CCCC

15 quarters

Position history for Man Group plcMan Group plc's holdings in C4 Therapeutics, Inc.

Yes. Man Group holds 408,648 shares of CCCC (C4 Therapeutics), worth $1.9M, as of its Q2 2026 13F filing. It increased the position by 152,180 shares (+59.3%) from Q1 2026. Man Group has held CCCC since Q1 2025, across 6 quarterly 13F filings.

Current Value

$1.9M

Current Shares

408,648

Total Value Change

+$1.7M

Total Shares Change

+403,225

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
408,648
+59.3%
$1.9M0.0%$4.67
37
2026-Q1
Increased
256,468
+64.3%
$674,5110.0%$2.63
36
2025-Q4
Increased
156,098
+72.9%
$298,1470.0%$1.91
35
2025-Q3
Increased
90,278
+15.0%
$200,4170.0%$2.22
26
2025-Q2
Decreased
78,487
-8.3%
$112,2360.0%$1.43
0
2025-Q1
New
85,623
-
$136,9970.0%$1.60
31
2024-Q2
Exited
0
-100.0%
$00.0%$4.62
0
2024-Q1
Decreased
139,900
-12.4%
$1.1M0.0%$8.17
0
2023-Q4
Increased
159,765
+5.7%
$902,6720.0%$5.65
26
2023-Q3
Increased
151,198
+118.1%
$281,2280.0%$1.86
38
2023-Q2
Increased
69,332
+72.8%
$190,6630.0%$2.75
34
2023-Q1
New
40,135
-
$126,0240.0%$3.14
31
2021-Q4
Exited
0
-100.0%
$00.0%$32.20
0
2021-Q3
Increased
6,423
+18.4%
$287,0000.0%$44.68
27
2021-Q2
New
5,423
-
$205,0000.0%$37.84
32

Other major holders of CCCC: T. Rowe Price Associates, Inc., RTW Investments, LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used